611 related articles for article (PubMed ID: 30249697)
1. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
[TBL] [Abstract][Full Text] [Related]
2. Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169).
Lupien A; Vocat A; Foo CS; Blattes E; Gillon JY; Makarov V; Cole ST
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126954
[TBL] [Abstract][Full Text] [Related]
3. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
Liu Y; Gao J; Du J; Shu W; Wang L; Wang Y; Xue Z; Li L; Xu S; Pang Y
Int J Infect Dis; 2021 Jan; 102():392-396. PubMed ID: 33130209
[TBL] [Abstract][Full Text] [Related]
4. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
[TBL] [Abstract][Full Text] [Related]
5. A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT.
Gao J; Gao M; Du J; Pang Y; Mao G; Lounis N; Bakare N; Jiang Y; Zhan Y; Liu Y; Li L;
Trials; 2024 Apr; 25(1):227. PubMed ID: 38561815
[TBL] [Abstract][Full Text] [Related]
6. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
[TBL] [Abstract][Full Text] [Related]
7. Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.
Sotgiu G; Tiberi S; Centis R; D'Ambrosio L; Fuentes Z; Zumla A; Migliori GB
Int J Infect Dis; 2017 Mar; 56():190-193. PubMed ID: 27816662
[TBL] [Abstract][Full Text] [Related]
8. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
[TBL] [Abstract][Full Text] [Related]
9. No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis.
Pang Y; Jing W; Lu J; Zong Z; Huo F; Dong L; Dai G; Li Y; Huang H; Chu N
Diagn Microbiol Infect Dis; 2019 Aug; 94(4):361-364. PubMed ID: 30876684
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition.
Yao C; Guo H; Li Q; Zhang X; Shang Y; Li T; Wang Y; Xue Z; Wang L; Li L; Pang Y
Antimicrob Resist Infect Control; 2021 Aug; 10(1):126. PubMed ID: 34446095
[TBL] [Abstract][Full Text] [Related]
11. Sub-MIC levels of bedaquiline and clofazimine can select
Villellas C; Stevenaert F; Remmerie B; Andries K
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0127523. PubMed ID: 38470194
[TBL] [Abstract][Full Text] [Related]
12. Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.
Tasneen R; Betoudji F; Tyagi S; Li SY; Williams K; Converse PJ; Dartois V; Yang T; Mendel CM; Mdluli KE; Nuermberger EL
Antimicrob Agents Chemother; 2016 Jan; 60(1):270-7. PubMed ID: 26503656
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
[TBL] [Abstract][Full Text] [Related]
14.
Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779
[TBL] [Abstract][Full Text] [Related]
15. Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens.
Riccardi N; Del Puente F; Magnè F; Taramasso L; Di Biagio A
Recent Pat Antiinfect Drug Discov; 2018; 13(1):3-11. PubMed ID: 28625141
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis.
Maartens G; Brill MJE; Pandie M; Svensson EM
Int J Tuberc Lung Dis; 2018 Jan; 22(1):26-29. PubMed ID: 29145924
[TBL] [Abstract][Full Text] [Related]
17. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.
Xu J; Wang B; Hu M; Huo F; Guo S; Jing W; Nuermberger E; Lu Y
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320727
[TBL] [Abstract][Full Text] [Related]
18. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK
Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125
[TBL] [Abstract][Full Text] [Related]
19. Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.
Li SY; Tasneen R; Tyagi S; Soni H; Converse PJ; Mdluli K; Nuermberger EL
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630203
[TBL] [Abstract][Full Text] [Related]
20. MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era.
Beckert P; Sanchez-Padilla E; Merker M; Dreyer V; Kohl TA; Utpatel C; Köser CU; Barilar I; Ismail N; Omar SV; Klopper M; Warren RM; Hoffmann H; Maphalala G; Ardizzoni E; de Jong BC; Kerschberger B; Schramm B; Andres S; Kranzer K; Maurer FP; Bonnet M; Niemann S
Genome Med; 2020 Nov; 12(1):104. PubMed ID: 33239092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
